Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X about a paper by Alexander Biederstädt et al. published in Cancer Cell:
“Genome-wide CRISPR screens unlock next-gen NK cell therapy potential
Multiple genome-wide CRISPR screens in primary human NK cells identified key checkpoints regulating resistance to tumor-induced immunosuppression.
- Knockout of MED12, CCNC, or ARIH2 enhanced NK cell antitumor potency
- Dual KO of ARIH2 + CCNC in CAR-NK cells boosted in vivo efficacy
- Editing improved NK cell metabolism, cytokine secretion, and cytotoxicity
This study provides a roadmap for engineering next-generation NK cell therapies with greater antitumor activity across refractory cancers.”
Title: Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency
Authors: Alexander Biederstädt, Rafet Basar, Jeong-Min Park, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, Merve Dede, John Watts, Sunil Acharya, Donghai Xiong, Bin Liu, May Daher, Hind Rafei, Pinaki Banerjee, Ping Li, Sanjida Islam, Huihui Fan, Mayra Shanley, Jingling Jin, Bijender Kumar, Vernikka Woods, Paul Lin, Silvia Tiberti, Ana Karen Nunez Cortes, Xin Ru Jiang, Inci Biederstädt, Patrick Zhang, Ye Li, Seema Rawal, Enli Liu, Luis Muniz-Feliciano, Gary M. Deyter, Elizabeth J. Shpall, Natalie Wall Fowlkes, Ken Chen, and Katayoun Rezvani
You can read the Full Article in Cancer Cell.
More posts featuring Yan Leyfman.